In cancer cells, TP53 mutations are associated with elevated HIF-1α levels, which augment the HIF-1α−dependent transcriptional activation of the VEGF gene in response to tumor hypoxia15, and mediate resistance to cancer therapy16. This evidence concerns the gene HIF1A and neoplasm.